ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
The Challenge for Development of Valuable Immuno-oncology Biomarkers.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review.International journal of molecular sciences · 2021Pooled it
- Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Pooled it
- Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Guideline
- Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer.Cancer science · 2020Trial
- Battlegrounds of treatment resistance: decoding the tumor microenvironment.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Immune infiltrate populations within distinct tumor immune microenvironments predictive of immune checkpoint treatment outcome.Scientific reports · 2025Article
- Network Medicine-Based Strategy Identifies Maprotiline as a Repurposable Drug by Inhibiting PD-L1 Expression via Targeting SPOP in Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- C-reactive protein to albumin ratio predict responses to programmed cell death-1 inhibitors in hepatocellular carcinoma patients.World journal of gastrointestinal oncology · 2024Article
- Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma.Clinical and experimental medicine · 2023Review
- Top-of-the-art cytometry as a novel tool to aid in lung cancer immunotherapy.Translational lung cancer research · 2023Article
- Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling.The Journal of clinical investigation · 2023Article
- Integration of liquid biopsy and immunotherapy: opening a new era in colorectal cancer treatment.Frontiers in immunology · 2023Review
- Challenges associated with the integration of immuno-oncology agents in clinical practice.BMC medical education · 2022Article
- Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis.World journal of surgical oncology · 2022Article
- Article
- Review
- ENPEP as a potential predictor of immune checkpoint inhibitor efficacy.Cancer medicine · 2022Article
- Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance.Frontiers in oncology · 2022Review
- Immuno-oncology trends: preclinical models, biomarkers, and clinical development.Journal for immunotherapy of cancer · 2022Review
- Targeting HSP90 sensitizes pancreas carcinoma to PD-1 blockade.Oncoimmunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The development of immunotherapy is an important breakthrough for the treatment of cancer, with antitumor efficacy observed in a wide variety of tumors. To optimize immunotherapy use, approaches must be developed to identify which patients are likely to achieve benefit. To minimize therapeutic toxicities and costs, understanding the ideal choice and sequencing of the numerous immuno-oncology agents available for individual patients is thus critical, but fraught with challenges. The immune tumor microenvironment (TME) is a unique aspect of the response to immuno-oncology agents and measurement of single biomarkers does not adequately capture these complex interactions. Therefore, multiple potential biomarkers are likely needed. Current candidates in this area include PD-L1 expression, CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.